Avalo Therapeutics

AVTX

Market cap $354M

19.51 USD

-0.44

2.21%

At close Updated Dec 11, 4:00 PM EST

Pre-market

After hours

19.00

-0.51

2.61%

1 day

-2.21%

5 days

9.48%

1 month

25.87%

3 months

79.32%

6 months

314.23%

Year to date

131.44%

1 year

107.77%

5 years

-99.75%

10 years

-99.78%

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23

Healthcare Biotechnology